Is Harvoni still used for hep C in modern pharmacology?
•
4 min read
Over 90% of chronic hepatitis C (HCV) cases can now be cured with well-tolerated, oral direct-acting antiviral (DAA) medications. The landmark drug Harvoni (ledipasvir/sofosbuvir) revolutionized this treatment landscape upon its 2014 approval, offering a highly effective, interferon-free regimen for specific genotypes. Although newer pan-genotypic therapies have emerged, Harvoni is still used for certain patient profiles and indications.
